Summary by Moomoo AI
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, has filed a preliminary proxy statement (PRE 14A) with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. The meeting will be conducted virtually via live webcast. The proxy statement outlines several key proposals, including the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an amendment to increase the authorized number of shares of common stock from 40,000,000 to 80,000,000. The company has adopted SEC rules allowing it to provide proxy materials over the Internet to reduce delivery costs and environmental impact. Stockholders will receive a notice with instructions on how to access the proxy materials and vote online. The proxy statement also includes an explanatory note detailing the company's history, including its incorporation as Locust Walk Acquisition Corp. in 2020, its merger with Old eFFECTOR, and subsequent name change to eFFECTOR Therapeutics, Inc. following the closing of the transactions on August 25, 2021.